RosaRex
- Manufacturer
- Feelgood Health | W.Last
- Effective date
- 2010-07-19
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 1
- Source
- full-release
- Hydrated at
- 2026-06-01 02:02:24
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
DESCRIPTION SECTION
Reduces facial redness, flushing and bumpy texture
INDICATIONS & USAGE SECTION
Indications: Homeopathic remedy for red, inflamed skin on the face.
DOSAGE & ADMINISTRATION SECTION
Dosage: Dissolve 2 tablets in a clean mouth 3 times daily. May be repeated every half hour if necessary. May be used with MediAc™ for combined support.
GENERAL PRECAUTIONS SECTION
Caution: If symptoms persist or worsen, a health care professional should be consulted. If pregnant or breastfeeding, ask a health professional before use. Keep this and all medicines from the reach of children.
OTC - ACTIVE INGREDIENT SECTION
Ingredients: Each dose contains equal parts of Carbo veg (30C) (HPUS), Calc phos (6X) (HPUS), Kali brom (30C) (HPUS), Calc sil (30C) (HPUS), Violo tric (6C) (HPUS)
INACTIVE INGREDIENT SECTION
Lactose (inactive ingredient).
PREGNANCY SECTION
If pregnant or breastfeeding, ask a health professional before use.
USER SAFETY WARNINGS SECTION
Contains no gluten, artificial flavors, colors or preservatives. Safe for all ages and during pregnancy.
INFORMATION FOR PATIENTS SECTION
All Native Remedies health products are especially formulated
by experts in the field of natural health and are manufactured according to the
highest pharmaceutical standards for maximum safety and effectiveness. For more
information, visit us at
www.nativeremedies.com
Distributed by
Native Remedies, LLC
6531 Park of Commerce Blvd.
Suite 160
Boca Raton, FL 33487
Phone: 1.877.289.1235
International: + 1.561.999.8857
The letters HPUS indicate that the component(s) in this product is (are) officially monographed in the Homeopathic Pharmacopoeia of the United States.
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Product Concepts#
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 68647-118-10 | 2019-10-21 | C162847 | 48780-1 | 956f9ecf-cad4-621f-e053-dbdaa90a74ad | ROSAREX |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 68647-118-10 | RosaRex | 125 in 1 BOTTLE, GLASS | TABLET | 125 | 1 |
DailyMed Dashboard NDC Coverage#
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ACTIVATED CHARCOAL | ACTIVE INGREDIENT | 2P3VWU3H10 | 1 | |
| CALCIUM SILICATE | ACTIVE INGREDIENT | S4255P4G5M | 1 | |
| POTASSIUM BROMIDE | ACTIVE INGREDIENT | OSD78555ZM | 1 | |
| TRIBASIC CALCIUM PHOSPHATE | ACTIVE INGREDIENT | 91D9GV0Z28 | 1 | |
| VIOLA TRICOLOR | ACTIVE INGREDIENT | 9Q24RAI43V | 1 | |
| ACTIVATED CHARCOAL | ACTIVE MOIETY | 2P3VWU3H10 | 1 | |
| CALCIUM CATION | ACTIVE MOIETY | 2M83C4R6ZB | 1 | |
| POTASSIUM CATION | ACTIVE MOIETY | 295O53K152 | 1 | |
| VIOLA TRICOLOR | ACTIVE MOIETY | 9Q24RAI43V | 1 | |
| LACTOSE | INACTIVE INGREDIENT | J2B2A4N98G | 1 |
Products#
Every source-derived product name is available through these pages.
- RosaRex
- Carbo veg, Calc phos , Kali brom, Calc sil Violo tric , Lactose .
- ACTIVATED CHARCOAL
- TRIBASIC CALCIUM PHOSPHATE
- CALCIUM CATION
- POTASSIUM BROMIDE
- POTASSIUM CATION
- CALCIUM SILICATE
- VIOLA TRICOLOR
- LACTOSE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 68647-118 | 68647-118-10 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| ACTIVATED CHARCOAL | 2P3VWU3H10 | ACTIB |
| TRIBASIC CALCIUM PHOSPHATE | 91D9GV0Z28 | ACTIB |
| POTASSIUM BROMIDE | OSD78555ZM | ACTIB |
| CALCIUM SILICATE | S4255P4G5M | ACTIB |
| VIOLA TRICOLOR | 9Q24RAI43V | ACTIB |
| LACTOSE | J2B2A4N98G | IACT |
Source Document#
Inactive ingredient matches#
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAVENOUS | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / ORAL | 530 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | OINTMENT / TOPICAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE / RESPIRATORY (INHALATION) | 44.4 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED PELLETS / ORAL | 135.2 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SUPPOSITORY / VAGINAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / RESPIRATORY (INHALATION) | 90 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION / INTRAMUSCULAR | 203.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, DELAYED RELEASE / ORAL | 160 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / RECTAL | 8 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, COATED, EXTENDED RELEASE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CREAM / VAGINAL | 3 %w/w | ||
| LACTOSE | LACTOSE | J2B2A4N98G | FILM, EXTENDED RELEASE / TRANSDERMAL | 675 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / ORAL | 2500 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, CHEWABLE / ORAL | 1412 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, COATED / ORAL | 332.05 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / BUCCAL | 296.7 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / SUBCUTANEOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, SOLUTION / INTRAVENOUS | 0.45 %w/v | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, SUGAR COATED / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER / VAGINAL | 430 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EXTENDED RELEASE / ORAL | 400 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / SUBLINGUAL | 352 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | GRANULE, FOR SUSPENSION / ORAL | 512.5 mg/5ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, DELAYED RELEASE / ORAL | 231.84 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRACAVITARY | 193.8 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 620 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | SOLUTION / ORAL | 1682 mg/15ml | ||
| LACTOSE | LACTOSE | J2B2A4N98G | POWDER, FOR SOLUTION / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, FILM COATED / ORAL | 590 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET, EFFERVESCENT / ORAL | 96.5 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 133 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | TABLET / RECTAL | 20 mg | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CONCENTRATE / ORAL | NA | ||
| LACTOSE | LACTOSE | J2B2A4N98G | CAPSULE, EXTENDED RELEASE / ORAL | 120 mg |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d54fc24a-a270-4997-9df2-e737bc85461b | 41fa88c2-9473-4386-bce4-4c03d254eab2 | 2010-07-19 | d54fc24a-a270-4997-9df2-e737bc85461b 41fa88c2-9473-4386-bce4-4c03d254eab2 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
